Pasithea Therapeutics upsizes ATM offering from $2.08M to $4.23M, adding $2.15M in new shares

Pasithea Therapeutics Corp.

Maximum aggregate offering price increased from $2,076,000 to $4,227,000 under November 2024 Sales Agreement with H.C. Wainwright.
Current Prospectus Supplement filed June 20, 2025, registering an additional $2,151,000 of common stock.
Approximately $2,075,688 in shares already sold under the prior ATM limit, nearly exhausting previous capacity.
Proceeds intended for general corporate purposes; dilution impact on existing shareholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.